The board of directors of Simcere Pharmaceutical Group Limited announced that, on January 3, 2024, the phase III clinical trial of Suvemcitug for injection combined with chemotherapy (the "Experimental Group") versus placebo combined with chemotherapy (the "Placebo Group") in patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (NCT04908787) (the "SCORES Study") has met the primary endpoint. The results include the final analysis of progression-free survival (the "PFS") as the primary endpoint, the first analysis of overall survival (the "OS") as the key secondary endpoint, and the safety analysis. The results showed: (1) the SCORES study has met the primary endpoint PFS which is assessed by the Blinded Independent Review Committee (BIRC) according to the RECIST 1.1 criteria.

Compared with the Placebo Group, the improvement of PFS in the Experimental Group is both statistically and clinically significant, and Suvemcitug has shown consistent PFS benefits among all pre-defined sub-groups. The PFS benefit of the Experimental Group evaluated by the researchers is consistent with those evaluated by BIRC; (2) the OS data are immature, but there is a trend of OS benefit in the Experimental Group; (3) the safety is manageable, no new safety signals are identified. The study results are expected to be released in academic journals or conferences in the future.

The Group plans to submit a New Drug Application (NDA) for Suvemcitug for injection in the treatment of platinum-resistant ovarian cancer to the National Medical Products Administration (NMPA) of China in the near future.